Concetta Lipardi

机构：Janssen (United States) · ORCID：0000-0002-3815-2259

发表论文 37 篇 · 总被引 1203 次 · h-index 13

代表论文

• Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis (2020 · TH Open · 被引 146)
• Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study (2019 · Clinical and Applied Thrombosis/Hemostasis · 被引 66)
• Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study (2021 · American Heart Journal · 被引 44)
• Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients (2021 · Journal of the American Heart Association · 被引 43)
• Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial (2023 · Circulation · 被引 30)
• Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials (2020 · Thrombosis and Haemostasis · 被引 19)